0 citations
Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice
Yearbook of pediatric endocrinology2020
Citations Over Time
Abstract
In brief: Antibody treatment against the Wnt antagonizing sclerostin substantially improves FGF23 levels, serum phosphate and mechanical bone properties in a murine model of X-linked hypophosphatemic rickets, suggesting a role of sclerostin in phosphate metabolism.
Related Papers
- → Sclerostin measurement in human disease: Validity and current limitations(2016)24 cited
- → Sclerostin Loop3 Participates in Whole-body Lipid and Glucose Metabolism Impairment Effects of Sclerostin(2023)1 cited
- → Serum Sclerostin as Biomarker in Osteogenesis Imperfecta(2015)1 cited
- → Serum Sclerostin as Biomarker in Osteogenesis Imperfecta(2017)1 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)